Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMA phase 3 study of garetosmab in fibrodysplasia ossificans progressiva
2023-508350-26-00Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in fibrodysplasia ossificans progressiva (FOP) comparing Garetosmab with Placebo matching to garetosmab (2 arms). Primary endpoints: Number of new heterotopic ossification lesions and Incidence and severity of treatment-emergent adverse events of special interest. Started Mar 2023; status: completed.
02
Drugs
garetosmab
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on 2023-508350-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508350-26-00.